When Harry Travis first met Neil Euliano and learned about his medication adherence technology, the pharmaceutical industry was beginning to usher in the age of pricey drugs with Hepatitis C therapies that hit the market at prices like $500 or $1,000 dollars a pill. “It just so happened at the time, really expensive medications were […]
Pharmaceuticals
Vertex invests in patient community and future docs with $500m commitment
Boston-based Vertex Pharmaceuticals (NSDQ:VRTX) announced today that it plans to spend $500 million over 10 years in support of an array of initiatives – including a $50 million investment in science, technology, engineering, arts and math education for underserved students and young women. Vertex is also extending its collaboration with Boston’s public school system, giving […]
Anika’s Monovisc therapy gets green light in Australia
Anika Therapeutics (NSDQ:ANIK) said yesterday that regulatory authorities in Australia approved the company’s single injection viscosupplement, Monovisc, for the treatment of pain associated with osteoarthritis of the synovial joints. This latest regulatory win means that Monovisc is commercially available in more than twenty countries, including the U.S. and Canada. The Bedford, Mass.-based company said it plans […]
Adventist Health System to use Glytec’s diabetes management system at 39 acute care facilities
Glytec has partnered with Adventist Health System to bring its eGlycemic diabetes management system to 39 of the health system’s acute care facilities. Glytec’s cloud-based eGMS will become a part of the standard of care for patients who need insulin therapy, in both the critical care units and on the medical-surgical floor, the companies said. […]
Researchers combine a smart phone, insulin pump and CGM in diabetes study
In a study published this week in Diabetes Care, researchers combined an insulin pump, a continuous glucose monitoring receiver and a smart phone with cloud-based algorithms to automatically monitor and adjust a patient’s glucose levels. The team pointed towards a number of systems that are designed to function as an artificial pancreas, but still require that […]
Johnson & Johnson pharma revenue continues to climb in Q3
Johnson & Johnson‘s (NYSE:JNJ) third quarter profits were down by -12%, the company reported today, but revenue topped expectations and the healthcare giant singled out its pharmaceutical business as a driving factor. “Johnson & Johnson accelerated growth in the third quarter. This is driven by the strong performance of our pharmaceutical business, and augmented by […]
Mylan: Allergan’s legal move with tribe reveals “duplicitousness” towards patent system
Allergan (NYSE:AGN) was dealt a major blow yesterday after a Texas judge ruled that claims to a number of patents for its dry eye drug, Restasis, were invalid due to obviousness. The ruling opens the door for generic versions of the drug that accounted for nearly 10% of Allergan’s revenue last year. The decision came […]
Texas judge rules Allergan’s Restasis patents invalid
U.S. judge William Bryson ruled that patents covering Allergan‘s (NYSE:AGN) Restasis medicine are invalid on the grounds of obviousness, driving the company’s shares down more than -6% in afternoon trading today. The decision, made in a Texas federal court, is part of an ongoing case between Allergan and generic drugmakers like Mylan (NSDQ:MYL) and Teva Pharmaceuticals […]
NanOlogy takes nanoparticle tech into Phase II trials
In the last two weeks, NanOlogy has launched trials evaluating its cancer-fighting paclitaxel nanoparticle suspension in patients with prostate cancer and in patients with ovarian cancer. The Texas-based company’s nanoparticle tech is based on a production process that cuts the size of chemotherapy crystals by up to 400 times, creating stable nanoparticles with increased surface […]
Insulet shareholder sues over OmniPod Eros
Insulet (NSDQ:PODD) shareholder Frank Carnazza filed a derivative suit against the Billerica, Mass-based company last week in a Massachusetts federal court, alleging that Insulet misrepresented the success of its OmniPod Eros roll-out in 2013, which eventually caused the shares in the company to plummet. Carnazza named a number of former and current executives in the suit, […]